How I Manage CML at MD Anderson in 2020: Are 1L Therapies Getting Better, Safer & Cheaper? Is There a Difference Between 2L Options? Is 3L Ponatinib Effective? Are Dose Reductions Effective and Safe? Is TFR Feasible?

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

Palliative & Supportive Care
Basic Science
COVID-19
Leukemia
Lymphoma
Myeloma
MDS and MPN
Benign Hematology
Lung
Business
Event

Playback speed

10 seconds

How I Manage CML at MD Anderson in 2020: Are 1L Therapies Getting Better, Safer & Cheaper? Is There a Difference Between 2L Options? Is 3L Ponatinib Effective? Are Dose Reductions Effective and Safe? Is TFR Feasible?

By XIth Eurasian Hematology-Oncology Congress - EHOC 2020 FEATURING Elias Jabbour

33 views

January 18, 2021

Comments 0

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison

Making the First Chance Count: Manuel

Feat. A. Ip

Leukemia

Pre-Pandemic CML Treatment: What Is CGA? How Do Ponatinib, Nilotinib…

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

P. Raanani

15 views

Challenges in Treatment of Leukemias and Bone Marrow Failure in Deve…

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

K. Rashid

15 views

AML Treatment in Developing Countries: LIMC vs. HIC Differences - St…

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

E. Rego

13 views

Cytogenetic Characterization in AML: How Do Gene Mutations Impact Ov…

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

M. Yilmaz

132 views

Targeted Therapy for Older Patients With AML: Is Addition of GO to I…

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

C. Schiffer

38 views

State of the Art in Adults With ALL: Salvage & 1L Ino and Blina + Ch…

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

E. Jabbour

23 views